Phase 3 Myeloma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been newly diagnosed with multiple myeloma and are not able to have a stem cell transplant.
- People whose disease was measurable at the time of diagnosis, shown by specific levels of certain proteins in the blood or urine (confirm with trial site for exact measurements).
- People who have completed 18 to 20 cycles of treatment with one of two specific drug combinations: daratumumab-lenalidomide-dexamethasone or isatuximab-lenalidomide-dexamethasone.
- People whose myeloma responded at least partially to that treatment, based on standard international guidelines from 2016.
- People with a general health and activity level rated between 0 and 3 on a standard medical scale, meaning they can at least carry out limited self-care (confirm with trial site).
- People who are able and willing to complete quality-of-life questionnaires in English, French, or another validated language provided by the trial.
- People who have given proper consent to participate, in line with local and regulatory requirements.
- People who are able to attend all required treatment visits and follow-up appointments.
- People for whom treatment can begin within 2 working days of joining the trial.
- People of childbearing potential who have agreed to use a highly effective method of contraception.
Who may not be able to join:
- People with a known history of certain related blood or protein disorders, specifically AL amyloidosis, POEMS syndrome, or Waldenström's macroglobulinemia.
- People currently receiving other cancer treatments that would interfere with following this trial's treatment plan (note: a history of a separate cancer, or a concurrent cancer that would not affect the trial's safety or results, may still be considered eligible — confirm with trial site).
- People who have had an active, uncontrolled bacterial, fungal, or viral infection in the 7 days before joining the trial.
- People who are HIV-positive with a CD4 cell count below 350 cells per microlitre, unless they meet all of the following conditions: they have been on antiretroviral therapy for at least 4 weeks before joining, with no significant drug interactions with the trial medications; their HIV viral load was below 400 copies per millilitre within the past 16 weeks; and they have had no opportunistic infections in the past year (confirm with trial site).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Hira Mian, Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario Canada
Phone: 613-533-6430
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Progression-Free Survival
Can't join this trial?
Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.